Caseware UK (AP4) 2023.0.135 2023.0.135 2023-07-312023-07-312022-08-01falsetruefalseGeneral medical practice activities21The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 12083097 2022-08-01 2023-07-31 12083097 2021-08-01 2022-07-31 12083097 2023-07-31 12083097 2022-07-31 12083097 c:Director1 2022-08-01 2023-07-31 12083097 d:MotorVehicles 2022-08-01 2023-07-31 12083097 d:MotorVehicles 2023-07-31 12083097 d:MotorVehicles 2022-07-31 12083097 d:MotorVehicles d:LeasedAssetsHeldAsLessee 2022-08-01 2023-07-31 12083097 d:FurnitureFittings 2022-08-01 2023-07-31 12083097 d:FurnitureFittings 2023-07-31 12083097 d:FurnitureFittings 2022-07-31 12083097 d:FurnitureFittings d:LeasedAssetsHeldAsLessee 2022-08-01 2023-07-31 12083097 d:OfficeEquipment 2022-08-01 2023-07-31 12083097 d:OfficeEquipment 2023-07-31 12083097 d:OfficeEquipment 2022-07-31 12083097 d:OfficeEquipment d:LeasedAssetsHeldAsLessee 2022-08-01 2023-07-31 12083097 d:ComputerEquipment 2022-08-01 2023-07-31 12083097 d:ComputerEquipment 2023-07-31 12083097 d:ComputerEquipment 2022-07-31 12083097 d:ComputerEquipment d:LeasedAssetsHeldAsLessee 2022-08-01 2023-07-31 12083097 d:LeasedAssetsHeldAsLessee 2022-08-01 2023-07-31 12083097 d:CurrentFinancialInstruments 2023-07-31 12083097 d:CurrentFinancialInstruments 2022-07-31 12083097 d:Non-currentFinancialInstruments 2023-07-31 12083097 d:Non-currentFinancialInstruments 2022-07-31 12083097 d:CurrentFinancialInstruments d:WithinOneYear 2023-07-31 12083097 d:CurrentFinancialInstruments d:WithinOneYear 2022-07-31 12083097 d:Non-currentFinancialInstruments d:AfterOneYear 2023-07-31 12083097 d:Non-currentFinancialInstruments d:AfterOneYear 2022-07-31 12083097 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-07-31 12083097 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2022-07-31 12083097 d:ShareCapital 2023-07-31 12083097 d:ShareCapital 2022-07-31 12083097 d:RetainedEarningsAccumulatedLosses 2023-07-31 12083097 d:RetainedEarningsAccumulatedLosses 2022-07-31 12083097 c:FRS102 2022-08-01 2023-07-31 12083097 c:AuditExempt-NoAccountantsReport 2022-08-01 2023-07-31 12083097 c:FullAccounts 2022-08-01 2023-07-31 12083097 c:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 12083097 6 2022-08-01 2023-07-31 iso4217:GBP xbrli:pure

Registered number: 12083097









G COLE CARDIOLOGY LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JULY 2023

 
G COLE CARDIOLOGY LIMITED
REGISTERED NUMBER: 12083097

STATEMENT OF FINANCIAL POSITION
AS AT 31 JULY 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
5,067
1,970

Investments
  
50,000
-

  
55,067
1,970

Current assets
  

Debtors: amounts falling due within one year
 6 
30,537
6,999

Cash at bank and in hand
 7 
40,002
82,673

  
70,539
89,672

Creditors: amounts falling due within one year
 8 
(45,853)
(30,242)

Net current assets
  
 
 
24,686
 
 
59,430

Total assets less current liabilities
  
79,753
61,400

Creditors: amounts falling due after more than one year
 9 
(2,688)
(4,040)

  

Net assets
  
77,065
57,360


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
76,965
57,260

  
77,065
57,360


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 April 2024.
Page 1

 
G COLE CARDIOLOGY LIMITED
REGISTERED NUMBER: 12083097
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 JULY 2023





Dr G Cole
Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
G COLE CARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

1.


General information

G Cole Cardiology Limited is a private company limited by shares incorporated in England and Wales (Reg No- 12083097) . The registered office is 101 New Cavendish Street, 1st Floor South, London, United Kingdom, W1W 6XH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 3

 
G COLE CARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Bicycles
-
20%
Straight line method
Fixtures and fittings
-
20%
Straight line method
Office equipment
-
20%
Straight line method
Computer equipment
-
20%
Straight line method

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Comprehensive Income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 4

 
G COLE CARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2022 - 1).


4.


Tangible fixed assets





Bicycles
Fixtures and fittings
Office equipment
Computer equipment
Total

£
£
£
£
£



Cost or valuation


At 1 August 2022
1,387
645
-
469
2,501


Additions
-
518
424
3,555
4,497



At 31 July 2023

1,387
1,163
424
4,024
6,998



Depreciation


At 1 August 2022
277
129
-
126
532


Charge for the year on financed assets
277
232
85
805
1,399



At 31 July 2023

554
361
85
931
1,931



Net book value



At 31 July 2023
833
802
339
3,093
5,067



At 31 July 2022
1,110
516
-
343
1,969

Page 5

 
G COLE CARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

5.


Fixed asset investments





Unlisted investments

£



Cost or valuation


Additions
50,000



At 31 July 2023
50,000





6.


Debtors

2023
2022
£
£


Trade debtors
4,805
3,500

Other debtors
15,405
-

Prepayments and accrued income
10,327
3,499

30,537
6,999



7.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
40,002
82,673

40,002
82,673



8.


Creditors: Amounts falling due within one year

2023
2022
£
£

Bank loans
1,353
1,319

Corporation tax
35,510
22,188

Other creditors
-
3,735

Accruals and deferred income
8,990
3,000

45,853
30,242


Page 6

 
G COLE CARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

9.


Creditors: Amounts falling due after more than one year

2023
2022
£
£

Bank loans
2,688
4,040

2,688
4,040



10.


Loans


Analysis of the maturity of loans is given below:


2023
2022
£
£

Amounts falling due within one year

Bank loans
1,352
1,319


1,352
1,319


Amounts falling due 2-5 years

Bank loans
2,688
4,040


2,688
4,040


4,040
5,359


 
Page 7